Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Anti-inflammatory Effects of Curcumin, Ginger and Piperine Supplementation in Ultra-trail Runners: a Double-blind Randomized Placebo-controlled Trial (ECUM-RUN)

21 septembre 2026 mis à jour par: Centre Hospitalier Universitaire de la Réunion

ECUM-RUN is a randomized, double-blind, placebo-controlled phase 3 trial evaluating whether a 30-day oral supplementation with curcumin, ginger, and piperine (9-5-1 formulation) reduces exercise-induced joint pain and inflammatory markers in 82 ultra-trail runners competing in the Diagonale des Fous (175 km). The primary endpoint is the change in knee pain (VAS score) between end of supplementation and race finish, compared between intervention and placebo groups.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • CHU de La Réunion
      • Saint-Pierre, CHU de La Réunion, France, 97400
        • Recrutement
        • Dr Nicolas BOUSCAREN
        • Contact:
          • PINARD
          • Numéro de téléphone: 0262353530
        • Contact:
          • Céleste

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age ≥ 18 years at inclusion
  • Registered for "La Diagonale des Fous" (Grand Raid de La Réunion, 175 km, 2026 edition)
  • Free, informed, signed consent obtained prior to any study-related procedure
  • Availability to participate in the full protocol, including preliminary consultations and biological sampling at all time points (T0 to T3)
  • Affiliated with or beneficiary of a social security scheme
  • Ability to understand and follow study instructions (sufficient French language level, or assistance available)

Exclusion Criteria:

  • Regular NSAID use in the 30 days prior to inclusion, defined as intake at least 3 days/week for at least 2 consecutive weeks, or ongoing treatment at the time of inclusion
  • Regular use of curcumin-containing supplements or "9-5-1"-type preparations in the 30 days prior to inclusion, defined as intake at least 3 days/week for at least 2 consecutive weeks
  • Taking anticoagulant treatment
  • History of hepatic, biliary, or pancreatic disease, including: gallstones, cholestasis, acute or chronic hepatitis, cirrhosis
  • Known allergy or documented hypersensitivity to any capsule component: turmeric, curcumin, ginger, black pepper, maltodextrin, or hydroxypropylmethylcellulose (HPMC)
  • Chronic inflammatory joint disease (e.g., rheumatoid arthritis, spondyloarthritis) under active specific treatment
  • Pregnancy or breastfeeding
  • Participation in another biomedical study involving a therapeutic intervention within the 30 days prior to inclusion
  • Severe cognitive or psychiatric impairment preventing understanding of the protocol or completion of questionnaires
  • Patient under guardianship/curatorship or subject to a legal protection order

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Contrôler

Capsule excipients are maltodextrin and hydroxypropylmethylcellulose (HPMC), allowing an identical-appearing placebo for double-blind conditions.

Expérimental: 9-5-1

The investigational intervention is an oral food-supplement capsule combining curcumin, ginger, and piperine in a proprietary "9-5-1" ratio (curcuma extract : ginger extract : black pepper/piperine extract), administered as 4 capsules per day for 30 consecutive days prior to the race.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Knee Pain Intensity from End of Supplementation to Race Finish (Visual Analog Scale)
Délai: From Day 30 (T1, end of the 30-day supplementation period) to race finish or withdrawal (T2) - up to approximately 60 hours later, corresponding to the maximum allowed race duration.

Knee pain is self-assessed using a Visual Analog Scale (VAS, 0-10 cm) at the end of the 30-day supplementation period (T1, day before the race) and immediately at race finish or withdrawal (T2). The primary outcome is the within-participant change in VAS score (T2 minus T1), compared between the curcumin-ginger-piperine (9-5-1) group and the placebo group.

From Day 30 (T1, end of the 30-day supplementation period) to race finish or withdrawal (T2) - up to approximately 60 hours later, corresponding to the maximum allowed race duration.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Kinetics of Joint Pain Across the Study Period (Ankles, Knees, Hips)
Délai: (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Pain intensity at the ankles, knees, and hips is self-assessed using a Visual Analog Scale (VAS, 0-10 cm) at each of the four measurement time points. Between-group differences (intervention vs. placebo) in the T2-T1 change are compared, and a mixed linear model is used to describe the overall pain trajectory from T0 to T3, accounting for repeated within-participant measures.

(T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in Joint Range of Motion (Ankles, Knees, Hips)
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Range of motion for each joint movement (in degrees) is measured by goniometry, separately for each joint and side, at each of the four time points. Between-group differences in the T2-T1 change in range of motion are compared for each joint tested.

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in circulating pro-inflammatory and anti-inflammatory cytokines (pg/mL)
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Venous blood samples are collected at each study visit to measure serum IL-1β, IL-6, IL-8, IL-1ra and IL-10 and TNF-α concentrations. Between-group differences in the T2-T1 change are compared for each cytokine, and mixed linear models describe their kinetics across T0-T3.

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in Inflammatory biomarkers (ng/mL)
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Venous blood samples are collected to measure serum calprotectin, resistin, and leptin concentrations. Between-group differences in the T2-T1 change are compared for each biomarker, and mixed linear models describe their kinetics across T0-T3.

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in serum enzyme activity (U/L)
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Venous blood samples are collected to measure serum creatine kinase (CK), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Between-group differences in the T2-T1 change are compared for each enzyme, and mixed linear models describe their kinetics across T0-T3.

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Oxidative stress and adiponectin (µmol/L)
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Venous blood samples are collected to measure serum malondialdehyde (MDA) and adiponectin. Between-group differences in the T2-T1 change are compared for each enzyme, and mixed linear models describe their kinetics across T0-T3.

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Changein serum creatinine (µmol/L)
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Venous blood samples are collected to measure serum creatinine. Between-group differences in the T2-T1 change are compared for each enzyme, and mixed linear models describe their kinetics across T0-T3.

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in blood urea (mmol/L)
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Venous blood samples are collected to measure in blood urea. Between-group differences in the T2-T1 change are compared for each enzyme, and mixed linear models describe their kinetics across T0-T3.

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Change in coagulation parameters
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Venous blood samples are collected to assess prothrombin time (PT, %) and international normalized ratio (INR). Between-group differences in the T2-T1 change are compared for each parameter, and mixed linear models describe their kinetics across T0-T3

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Clinical tolerance
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Clinical tolerance is assessed at each study visit by recording digestive symptoms, allergic reactions, and other adverse events.

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)
Biological safety laboratory parameters
Délai: Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Biological safety is assessed using routine laboratory parameters evaluating liver function, renal function, and coagulation throughout the study.

Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

14 septembre 2026

Achèvement primaire (Estimé)

20 octobre 2026

Achèvement de l'étude (Estimé)

20 octobre 2026

Dates d'inscription aux études

Première soumission

2 juillet 2026

Première soumission répondant aux critères de contrôle qualité

8 juillet 2026

Première publication (Réel)

13 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

22 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

21 septembre 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2025/RUN/0056
  • 2026-A00478-43 (Autre identifiant: ID-RCB)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner